Inflammasomes driven inflammation in lung cancer revisited: a short review-Reference-Cited by-同舟云学术

Inflammasomes driven inflammation in lung cancer revisited: a short review

Published:2023-03-14 Issue: Volume: Page:70-81
ISSN:2768-6655
Container-title:Exploration of Immunology
language:en
Short-container-title:Explor Immunol

Author:

da Costa Vitor Rodrigues¹^ORCID,Souza Olívia Fonseca²^ORCID,Teixeira Michelli Ramires³^ORCID,Alievi Anderson Lucas³^ORCID,Vigerelli Hugo⁴^ORCID,Araldi Rodrigo Pinheiro⁵^ORCID

Affiliation:

1. Programa de Pós-Graduação em Biologia Estrutural e Funcional, Escola Paulista de Medicina (EPM), Federal University of São Paulo (UNIFESP), São Paulo 04039-032, Brazil; Genetics Laboratory, Instituto Butantan, São Paulo 05508-010, Brazil

2. Laboratory of Ontogeny of Lymphocytes, Departamento de Microbiologia, Imunologia e Parasitologia, Federal University of São Paulo (UNIFESP), São Paulo 04039-032, Brazil

3. Genetics Laboratory, Instituto Butantan, São Paulo 05508-010, Brazil; Programa de Pós-Graduação em Endocrinologia e Metabologia, Escola Paulista de Medicina (EPM), Federal University of São Paulo (UNIFESP), São Paulo 04022-001, Brazil

4. Genetics Laboratory, Instituto Butantan, São Paulo 05508-010, Brazil

5. Programa de Pós-Graduação em Biologia Estrutural e Funcional, Escola Paulista de Medicina (EPM), Federal University of São Paulo (UNIFESP), São Paulo 04039-032, Brazil; Genetics Laboratory, Instituto Butantan, São Paulo 05508-010, Brazil; BioDecision Analytics, São Paulo-SP 05713-510, Brazil

Abstract

Lung cancer is the leading cause of cancer-related deaths worldwide. The main risk factor for lung cancer is exposure to chemicals present in cigarettes and atmospheric pollutants, which, among other mechanisms, can increase the risk of cancer by inducing pulmonary inflammation. Among the complex features of inflammatory processes, the role of inflammasomes has attracted increasing attention due to their role in different stages of carcinogenesis. Inflammasomes are intracellular multiprotein complexes that when activated promote the maturation of interleukin-1beta (IL-1β) and IL-18, pro-inflammatory cytokines involved in the promotion, progression, epithelial-mesenchymal transition, metastasis, and resistance to therapy of lung cancer. In this way, this review summarizes the recent findings of inflammasome research in different stages of lung cancer, with a focus on non-small cell lung carcinoma (NSCLC), and highlights these multiprotein complexes as promising targets for cancer therapy.

Publisher

Open Exploration Publishing

Reference86 articles.

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

2. Tubin S, Khan MK, Gupta S, Jeremic B. Biology of NSCLC: interplay between cancer cells, radiation and tumor immune microenvironment. Cancers. 2021;13:775.

3. Aradi RP, Teixeira MR, Alievi AL, Rodrigues da Costa V, Correa de Melo T, Barreiros de Souza E, et al. Molecular profile of non-small cell lung cancer cell lines A549 and H460 affects the response against cyclophosphamide and acid hydrolysis extract of agave sisalana (AHEAS). J Oncology. 2022;2:1018.

4. Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, et al. Non-small-cell lung cancer. Nat Rev Dis Primers. 2015;1:15009.

5. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553:446–54.